Advesya Granted EMA Clinical Trial Application (CTA) for CCTx-001, Its Lead Investigational Cell Therapy Asset Targeting IL-1RAP for the Treatment of Relapsed/Refractory Acute Myeloid Leukaemia Paris – July 29th 2024 – Advesya, a pioneering biopharma company focusing on targeting IL-1RAP for the treatment of difficult-to-treat cancers [...]
CCTx-001, A FIRST IN CLASS AUTOLOGOUS ANTI-IL-1RAP CAR T-CELL THERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY AML Topic: Acute myeloid leukemia – Biology & translational research Background: Relapsed/refractory acute myeloid leukaemia (r/AML) poses significant therapeutic challenges, necessitating novel treatment strategies. While allogeneic hematopoietic stem cell transplantation remains the only curative option, [...]
Advesya Granted EMA Clinical Trial Application (CTA) for CCTx-001, Its Lead Investigational Cell Therapy Asset Targeting IL-1RAP for the Treatment of Relapsed/Refractory Acute Myeloid Leukaemia Paris [...]
CCTx-001, A FIRST IN CLASS AUTOLOGOUS ANTI-IL-1RAP CAR T-CELL THERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY AML Topic: Acute myeloid leukemia – Biology & translational research Background: Relapsed/refractory acute myeloid leukaemia [...]
Abstract 6322: CCTx-001 CAR T-cells targeting the AML specific antigen IL-1RAP show robust pre-clinical anti-tumor efficacy Abstract Despite significant advancements in acute myeloid leukemia (AML) treatment, patients with relapsed/refractory (r/r) [...]
Abstract 2360: ADV101, a first-in-class IL-1RAP ADC demonstrates significant anti-tumor activity in solid tumor models Abstract Chronic inflammation is intricately linked to cancer development, and the IL-1 cytokine family stands [...]
Ksenija Pavletic’s interview on BFM Business France In an insightful TV interview, Advesya’s CEO, Ksenija Pavletic, details the company’s mission to transform cancer care. The company emphasized its advances in [...]
© 2024 advesya | All rights reserved
